IRIS

This chapter explores the different CTLA-4, PD-1 and PD-L1 inhibitors that have been investigated in advanced NSCLC, analyzing the different studies that have been performed, the evidences obtained, and the role in the clinical management of patients.

Immunotherapy / Viscardi, G.; Russo, G. L.; Ferrara, R.; Garassino, M. C.. - (2023), pp. 283-304. [10.1016/B978-0-323-69573-2.00022-X]

Immunotherapy

Ferrara R.
Penultimo
;
2023-01-01

Abstract

This chapter explores the different CTLA-4, PD-1 and PD-L1 inhibitors that have been investigated in advanced NSCLC, analyzing the different studies that have been performed, the evidences obtained, and the role in the clinical management of patients.
2023
Inglese
Lung Cancer: an Evidence-Based Approach to Multidisciplinary Management
Elsevier
283
304
22
2-s2.0-85189392457
https://www.sciencedirect.com/science/article/abs/pii/B978032369573200022X?via=ihub
Esperti anonimi
Sì
Internazionale
Goal 3: Good health and well-being
atezolizumab
avelumab
checkpoint inhibitors
immune
immunotherapy
nivolumab
NSCLC
PD-1
PD-L1
pembrolizumab
No
2 Contributo in Volume::2.1 Contributo in volume (Capitolo o Saggio)
4
268
Immunotherapy / Viscardi, G.; Russo, G. L.; Ferrara, R.; Garassino, M. C.. - (2023), pp. 283-304. [10.1016/B978-0-323-69573-2.00022-X]
none
Viscardi, G.; Russo, G. L.; Ferrara, R.; Garassino, M. C.
info:eu-repo/semantics/bookPart
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11768/176597
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? ND
social impact